Search

Fibralign set to bring new device option for secondary lymphedema

A young company developing a product to address secondary lymphedema, a chronic disease with no cure, stole the show at a venture competition held during a recent medical device conference. Working with Stanford University (Stanford, California), Fibralign (Sunnyvale, California) developed BioBridge, a surgical device designed to support the formation of new functional lymphatic vessels. The company has completed a large animal study to validate the technology and is now preparing for a clinical study. Fibralign was voted the winner of the annual MedTech Innovator competition by an audience at the 22nd annual medical device conference hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR

WHO WE ARE

Fibralign Corporation is a developer of advanced therapeutic devices that utilizes Nanoweave ®, a proprietary scaffolding technology for addressing unmet medical needs.

Read More >

QUICK LINKS
GET IN TOUCH